Newsfile Corp
11 Aug 2026, 12:44 UTC · 1h ago
NTHI Brain Cancer Phase 2 Data Expected to Spark Triple Confluence
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Newsfile Corp
11 Aug 2026, 12:44 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
NeOnc Technologies (NTHI) will release topline Phase 2a results for its NEO100 therapy in recurrent IDH1-mutant high-grade glioma on August 12 at 8:30 a.m. ET. — Clinical trial results for a brain cancer treatment are binary catalysts that typically cause extreme price volatility in small-cap biotech stocks.
+0.80The stock currently features a combination of a low float and elevated short interest. — These technical conditions can amplify upward price movements (short squeeze) if the upcoming clinical data is positive.
+0.40Which stocks this story touches
The company is positioned for a 'high impact catalyst day' with upcoming Phase 2a clinical results and a favorable technical setup.
Continue reading
6 related stories
Top 3 movers · tap to explore
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Seeking Alpha
8h ago
